zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2011-8-2s-27zdor-1203Research ArticleБез разделаОСТРЫЙ МИЕЛОБЛАСТНЫЙ ЛЕЙКОЗ, РАЗВИВШИЙСЯ ПОСЛЕ ТЕРАПИИ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ ИЛИ ПРИОБРЕТЕННОЙ АПЛАСТИЧЕСКОЙ АНЕМИИ В ДЕТСКОМ ВОЗРАСТЕACUTE MYELOBLASTIC LEUKEMIA DEVELOPING AFTER THE TREATMENT FOR MALIGNANT NEOPLASM OR APLASTIC ANEMIA ACQUIRED IN CHILDHOODРомашевскаяИ. П.RomashevskayaI. P.noemail@neicon.ruСавваН. Н.SavvaN. N.noemail@neicon.ruЛитвинкоН. П.LitvinkoN. P.noemail@neicon.ruАлейниковаО. В.AleinikovaO. V.noemail@neicon.ruРеспубликанский научно-практический центр детской онкологии и гематологииRepublican Research Centre for Pediatric Oncology and HematologyРеспубликанский научно-практический центр радиационной медицины и экологии человекаRepublican Research Centre for Radiation Medicine and Human Ecology20112812201102S7981Copyright © Ромашевская И.П., Савва Н.Н., Литвинко Н.П., Алейникова О.В., 20112011Ромашевская И.П., Савва Н.Н., Литвинко Н.П., Алейникова О.В.Romashevskaya I.P., Savva N.N., Litvinko N.P., Aleinikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1203

В статье представлены 8 случаев вторичного острого миелобластного лейкоза (ОМЛ) у больных, получивших лечение по поводу злокачественного новообразования (ЗН) или приобретенной апластической анемии (ПАА) в детском возрасте, и 40 случаев de novo ОМЛ группы высокого риска. Дискутируется клинико-лабораторная характеристика, терапия и выживаемость вторичного ОМЛ и de novo ОМЛ с учетом имеющихся на сегодняшний день литературных данных.

The article presents 8 cases of secondary acute myeloblastic leukemia in patients, undergoing the treatment for a malignant neoplasm or anplastic anemia acquired in childhood and 40 cases of de novo acute myeloblastic leukemia of the high risk group. The clinical laboratory characteristics, therapy and survival rate of secondary acute myeloblastic leukemia and de novo acute myeloblastic leukemia have been discussed in the article with the account of the literary up-to-date data.

вторичный или терапией обусловленный ОМЛde novo ОМЛдетиsecondary acute myeloblastic leukemia or therapy-associated acute myeloblastic leukemiade novo acute myeloblastic leukemiachildrenReferencesБИБЛИОГРАФИЧЕСКИЙ СПИСОКБИБЛИОГРАФИЧЕСКИЙ СПИСОКThe incidence of secondary leukemias / G. Leone [et al.] // Haematologica. - 1999. - Vol. 84. - P. 937-945.The incidence of secondary leukemias / G. Leone [et al.] // Haematologica. - 1999. - Vol. 84. - P. 937-945.Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation / D. Barnard [et al.] // Blood. - 2002. - Vol. 100. - P. 427-434.Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation / D. Barnard [et al.] // Blood. - 2002. - Vol. 100. - P. 427-434.Therapy-related leukemia and myelodysplasia: susceptibility and incidence / G. Leone [et al.] // Haematologica. - 2007. - Vol. 92(10). - P. 1389-1398.Therapy-related leukemia and myelodysplasia: susceptibility and incidence / G. Leone [et al.] // Haematologica. - 2007. - Vol. 92(10). - P. 1389-1398.Acute myeloid leukemia in patients previously diagnosed with breast cancer: еxperience of the GIMEMA group / L. Pagano [et al.] // Annals of oncology. - 2001. - Vol. 12. - P. 203-207.Acute myeloid leukemia in patients previously diagnosed with breast cancer: еxperience of the GIMEMA group / L. Pagano [et al.] // Annals of oncology. - 2001. - Vol. 12. - P. 203-207.Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia / C. H. Pui [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 7936-7941.Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia / C. H. Pui [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 7936-7941.Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1974-2001 and on 5098 unselected cases reported in the literature 1974-2001 / N. Mauritzson [et al.] // Leukemia. - 2002. - Vol. 16. - P. 2366-2378.Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1974-2001 and on 5098 unselected cases reported in the literature 1974-2001 / N. Mauritzson [et al.] // Leukemia. - 2002. - Vol. 16. - P. 2366-2378.Pedersen-Bjergaard, J. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation / J. Pedersen-Bjergaard, J. D. Rowley // Blood. - 1994. - Vol. 83. - P. 2780-2786.Pedersen-Bjergaard, J. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation / J. Pedersen-Bjergaard, J. D. Rowley // Blood. - 1994. - Vol. 83. - P. 2780-2786.Pedersen-Bjergaard, J. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II / J. Pedersen-Bjergaard, P. Phillip // Blood. - 1991. - Vol. 78. - P. 1147-1148.Pedersen-Bjergaard, J. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II / J. Pedersen-Bjergaard, P. Phillip // Blood. - 1991. - Vol. 78. - P. 1147-1148.Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting at DNA-topoisomerase II / H. J. Gilr [et al.] // Blood. - 1993. - Vol. 82. - P. 3705-3711.Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting at DNA-topoisomerase II / H. J. Gilr [et al.] // Blood. - 1993. - Vol. 82. - P. 3705-3711.Pedersen-Bjergaard, J. Two different classes of therapy-related and de novo acute myeloid leukemia? / J. Pedersen-Bjergaard, P. Philip // Cancer Genet. Cytogenet. - 1991. - Vol. 55. - P. 119-124.Pedersen-Bjergaard, J. Two different classes of therapy-related and de novo acute myeloid leukemia? / J. Pedersen-Bjergaard, P. Philip // Cancer Genet. Cytogenet. - 1991. - Vol. 55. - P. 119-124.Risk factors for evolutions of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children / S. Kojima [et al.] // Blood. - 2002. - Vol. 100. - P. 786-790.Risk factors for evolutions of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children / S. Kojima [et al.] // Blood. - 2002. - Vol. 100. - P. 786-790.Genetics of therapy-related myelodysplasia and acute myeloid leukemia / J. Pedersen-Bjergaard [et al.] // Leukemia. - 2008. - Vol. 22. - P. 240-248.Genetics of therapy-related myelodysplasia and acute myeloid leukemia / J. Pedersen-Bjergaard [et al.] // Leukemia. - 2008. - Vol. 22. - P. 240-248.Secondary acute myeloid leukemia: results of conventional treatments: еxperience of GIMEMA trials / L. Pagano [et al.] // Annals of oncology. - 2005. - Vol. 16 (2). - P. 228-233.Secondary acute myeloid leukemia: results of conventional treatments: еxperience of GIMEMA trials / L. Pagano [et al.] // Annals of oncology. - 2005. - Vol. 16 (2). - P. 228-233.Toxicity and outcome of children with treatment related acute myeloid leukemia / U. Tabori [et al.] // Pediatr Blood Cancer. - 2008. - Vol. 50. - P. 17-23.Toxicity and outcome of children with treatment related acute myeloid leukemia / U. Tabori [et al.] // Pediatr Blood Cancer. - 2008. - Vol. 50. - P. 17-23.Rowe, J. Therapy of secondary leukemia / J. Rowe [et al.] // Leukemia. - 2002. - Vol. 16. - P. 748-750.Rowe, J. Therapy of secondary leukemia / J. Rowe [et al.] // Leukemia. - 2002. - Vol. 16. - P. 748-750.Prognosis in therapy-related acute myeloid leukemia and impact of karyotype / W. Kern [et al.] // J. Clin. Oncol. - 2004. - Vol. 22. - P. 2510-2511.Prognosis in therapy-related acute myeloid leukemia and impact of karyotype / W. Kern [et al.] // J. Clin. Oncol. - 2004. - Vol. 22. - P. 2510-2511.

The authors declare that there are no conflicts of interest present.